McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Apple Turns 50: From Garage Startup to AI Crossroads 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
NEW YORK, Dec. 12, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the American Depositary Shares (“ADSs”) of Teva Pharmaceutical Industries Limited (NYSE:TEVA) between February 10, 2015 and November 3, 2016, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Teva investors under the federal securities laws.
To join the Teva class action, go to http://www.rosenlegal.com/cases-979.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Teva was engaging and/or had engaged in conduct that would result in an antitrust investigation by the U.S. Department of Justice (“DOJ”) and the State of Connecticut Office of the Attorney General; (2) the DOJ investigation and the underlying conduct could cause U.S. prosecutors to file criminal charges against Teva by the end of 2016 for suspected price collusion; (3) in turn, Teva lacked effective internal controls over financial reporting; and (4) as a result, Teva’s public statements were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 5, 2017. If you wish to join the litigation, go to: http://www.rosenlegal.com/cases-979.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
